DAFNA Capital Management LLC Buys 249,275 Shares of Inogen, Inc $INGN

Key Points

• DAFNA Capital Management LLC significantly increased its holdings in Inogen, Inc by 119.4%, owning a total of 458,065 shares after purchasing an additional 249,275 shares in the first quarter.
• Analysts have mixed opinions about Inogen, with a consensus rating of "Moderate Buy" and a price target averaging $11.00, while some raised and others lowered their targets recently.
• Inogen recently reported better-than-expected quarterly earnings, with a revenue of $92.28 million, surpassing analyst estimates of $90.40 million.

DAFNA Capital Management LLC raised its stake in Inogen, Inc (NASDAQ:INGN - Free Report) by 119.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 458,065 shares of the medical technology company's stock after purchasing an additional 249,275 shares during the period. Inogen accounts for approximately 0.9% of DAFNA Capital Management LLC's investment portfolio, making the stock its 26th biggest position. DAFNA Capital Management LLC owned approximately 1.70% of Inogen worth $3,266,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of INGN. Nuveen LLC acquired a new position in shares of Inogen in the first quarter valued at $1,097,000. Royce & Associates LP increased its holdings in shares of Inogen by 42.8% in the first quarter. Royce & Associates LP now owns 444,457 shares of the medical technology company's stock valued at $3,169,000 after purchasing an additional 133,258 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Inogen by 25.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 607,837 shares of the medical technology company's stock valued at $5,574,000 after purchasing an additional 123,208 shares during the last quarter. Monaco Asset Management SAM boosted its position in shares of Inogen by 119.1% in the first quarter. Monaco Asset Management SAM now owns 167,594 shares of the medical technology company's stock valued at $1,195,000 after acquiring an additional 91,094 shares during the period. Finally, Millennium Management LLC boosted its position in shares of Inogen by 162.5% in the fourth quarter. Millennium Management LLC now owns 143,653 shares of the medical technology company's stock valued at $1,317,000 after acquiring an additional 88,924 shares during the period. 89.94% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on INGN. B. Riley began coverage on shares of Inogen in a research report on Monday, June 16th. They issued a "buy" rating and a $14.00 target price for the company. Needham & Company LLC raised shares of Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 target price for the company in a research report on Thursday, May 22nd. Finally, Stifel Nicolaus reduced their target price on shares of Inogen from $10.00 to $7.00 and set a "hold" rating for the company in a research report on Thursday, May 8th. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $11.00.

Inogen Price Performance

INGN traded up $0.37 on Thursday, hitting $8.25. 93,197 shares of the stock were exchanged, compared to its average volume of 273,723. Inogen, Inc has a 12 month low of $5.70 and a 12 month high of $12.91. The business has a 50-day moving average of $7.10 and a two-hundred day moving average of $7.16. The firm has a market capitalization of $222.94 million, a price-to-earnings ratio of -7.79 and a beta of 1.78.

Inogen (NASDAQ:INGN - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical technology company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.07. The business had revenue of $92.28 million during the quarter, compared to analysts' expectations of $90.40 million. Inogen had a negative net margin of 7.58% and a negative return on equity of 13.77%. Inogen has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts expect that Inogen, Inc will post -1.73 earnings per share for the current fiscal year.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.